Novartis | NVS - Net Income

Stock Price
154.01
Daily Change
4.22 2.82%
Monthly
11.71%
Yearly
40.25%
Q1 Forecast
145.07

Novartis reported $3.93B in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 186M 752M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.53B 83M Sep/2025
Bausch Health Companies USD 179M 31M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 2.2B 891M Sep/2025
Canopy Growth CAD -1.64M 39.89M Sep/2025
Corcept Therapeutics USD 19.67M 15.48M Sep/2025
Drreddys Laboratories INR 12.1B 2.08B Dec/2025
Eli Lilly USD 5.58B 78M Sep/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
GlaxoSmithKline GBP 2.01B 570M Sep/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
J&J USD 5.12B 36M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Pacira USD 5.43M 10.28M Sep/2025
Perrigo USD 7.5M 15.9M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prestige Brands USD 69.13M 7.36M Sep/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
Zoetis USD 721M 3M Sep/2025